

Alan Hruza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12009442/publications.pdf>

Version: 2024-02-01

22
papers

1,894
citations

623734

14
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

3169
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. <i>Cancer Discovery</i> , 2013, 3, 742-750.	9.4	559
2	Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. <i>Nature Structural Biology</i> , 1999, 6, 233-242.	9.7	397
3	Zinc mediated dimer of human interferon- β revealed by X-ray crystallography. <i>Structure</i> , 1996, 4, 1453-1463.	3.3	236
4	Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis. <i>Nature</i> , 2018, 556, 122-125.	27.8	184
5	Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 204-208.	2.8	134
6	Structure-guided discovery of cyclin-dependent kinase inhibitors. <i>Biopolymers</i> , 2008, 89, 372-379.	2.4	51
7	Dissecting Therapeutic Resistance to ERK Inhibition. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 548-559.	4.1	50
8	Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6220-6223.	2.2	49
9	Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5170-5174.	2.2	35
10	Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6216-6219.	2.2	32
11	Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 214-218.	2.8	31
12	Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6501-6511.	6.4	26
13	A homology model of human interferon β -2. <i>Proteins: Structure, Function and Bioinformatics</i> , 1993, 17, 62-74.	2.6	24
14	Development of a novel class of potent and selective FIXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4945-4949.	2.2	16
15	Development of a novel tricyclic class of potent and selective FIXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5437-5443.	2.2	16
16	Rapid development of two factor IXa inhibitors from hit to lead. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2321-2325.	2.2	14
17	Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3544-3549.	2.2	11
18	Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2029-2034.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2622-2628.	2.2	10
20	Discovery of a highly potent orally bioavailable imidazo-[1, 2- a]pyrazine Aurora inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1397-1403.	2.2	4
21	Structure of the Insulin Receptor in Complex with Insulin using Single Particle CryoEM Analysis. <i>Microscopy and Microanalysis</i> , 2017, 23, 1186-1187.	0.4	3
22	Discovery of hydroxy pyrimidine Factor IXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127279.	2.2	1